Steering Committee
BioCentury's Scientific Advisory Board brings together top leaders from pharma, biotech, venture and academia and serves as a Steering Committee for the Grand Rounds R&D conference.
Amy Abernethy, M.D., Ph.D.
Former Principal Deputy Commissioner
FDA
Noubar Afeyan, Ph.D.
Founder & CEO
Flagship Pioneering
Houman Ashrafian, D.Phil.
EVP of R&D
Sanofi
Kate Bingham
Managing Partner
SV Health Investors
Melissa Bonner, Ph.D.
CSO
Nvelop Therapeutics
Luciana Borio, M.D.
Venture Partner
Arch Venture Partners
Shelley Chu, M.D., Ph.D.
Partner, Head of Biotech
Lightspeed Ventures
Francesco De Rubertis, Ph.D.
Co-Founder & Partner
Medicxi
Aaron Esser-Kahn, Ph.D.
Professor of Molecular Engineering
University of Chicago
Todd Foley
Managing Director
MPM BioImpact
David Goldstein, Ph.D.
Co-founder & CEO
Actio Biosciences
Anika Gupta, Ph.D.
Principal
GV
Colin Hill
Cofounder and CEO
Aitia
Najat Khan, Ph.D.
Chief Data Science Officer
Johnson & Johnson
Sophie Kornowski, Pharm.D.
CEO
Boston Pharmaceuticals
John Lepore, M.D.
CEO
ProFound Therapeutics
Mathai Mammen, M.D., Ph.D.
Chairman & CEO
FogPharma
Gregory Newby, Ph.D.
Assistant Professor
Johns Hopkins University
Antoine Papiernik
Chairman & Managing Partner
Sofinnova Partners
Kush Parmar, M.D., Ph.D.
Managing Partner
5AM Ventures
Cary Pfeffer, M.D.
Partner
Third Rock Ventures
Andrew Plump, M.D., Ph.D.
President of R&D
Takeda Pharmaceutical Co. Ltd.
James Sabry, M.D., Ph.D.
EVP and CBO
BioMarin Pharmaceutical Inc.
Otello Stampacchia, Ph.D.
Founder and Managing Director
Omega Funds
Paul Peter Tak, M.D., Ph.D.
President and CEO
Candel Therapeutics
Marc Tessier-Lavigne, Ph.D.
Professor
Stanford University
Jan van de Winkel, Ph.D.
President and CEO
Genmab A/S
Douglas Williams, Ph.D.
CEO
TriArm Therapeutics